For the Inventor, By the Inventor

Enter assignee name

Munich, Germany

Micromet Ag

USPTO Granted Patents = 25

% Expired Patents = 24.0

EPO Patents = 6

Trademarks = 1

Forward Citations = 993

Loading Chart...

Loading Chart...

66 inventors (with patents filed for the assignee):

Peter Kufer (13 out of 65 patents)

Tobias Raum (9 out of 60 patents)

Ralf Lutterbüse (6 out of 26 patents)

4. Patrick A Baeuerle (5 out of 35 patents)

5. Birgit Kohleisen (4 out of 7 patents)

6. Andreas Wolf (3 out of 16 patents)

7. Ulla Lenkkeri-Schütz (3 out of 5 patents)

8. Patrick Bäuerle (3 out of 7 patents)

9. Doris Rau (2 out of 27 patents)

10. Steven Zeman (2 out of 5 patents)

11. Christian Itin (2 out of 5 patents)

12. Meera Berry (2 out of 4 patents)

13. Bernd Dorken (2 out of 2 patents)

14. Gert Riethmuller (2 out of 2 patents)

15. Ralf Bargou (2 out of 2 patents)

25 patents: Sort by Forward Citations

1. 8840888 - Dosage regimen for administering a CD19XCD3 bispecific antibody (2014-09-23),

2. 8394926 - Pharmaceutical compositions with resistance to soluble CEA (2013-03-12),

3. 8247194 - Preparation of scFv antibody fragments (2012-08-21),

4. 8236308 - Composition comprising cross-species-specific antibodies and uses thereof (2012-08-07),

5. 8101722 - Less immunogenic binding molecules (2012-01-24),

6. 8076459 - Multispecfic deimmunized CD3-binders (2011-12-13),

7. 8017748 - Antibody neutralizers of human granulocyte macrophage colony stimulating factor (2011-09-13),

8. 8007796 - Means and methods for the treatment of tumorous diseases (2011-08-30),

9. 7976842 - Treatment of metastatic breast cancer (2011-07-12),

10. 7964707 - Anti-IL2 antibodies (2011-06-21),

11. 7919089 - Pharmaceutical composition comprising a bispecific antibody for EpCAM (2011-04-05),

12. 7820166 - Potent T cell modulating molecules (2010-10-26),

13. 7635472 - Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders (2009-12-22),

14. 7632925 - Antibodies that bind human 17-A1/EpCAM tumor antigen (2009-12-15),

15. 7575923 - CD19xCD3 specific polypeptides and uses thereof (2009-08-18),

Micromet AG is a global biopharmaceutical company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer. With a strong emphasis on research and development, Micromet AG aims to provide targeted solutions to unmet medical needs. Through strategic partnerships and collaborations, the company continues to advance its cutting-edge therapies to improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 22 2026

25 Patents

#113 in W-8000 Munich

#1,842 in Germany

#25,627 in the World

Munich, Germany

Micromet Ag

Forward Citations = 993

66 inventors:

Peter Kufer (13 out of 65 patents)

Tobias Raum (9 out of 60 patents)

Ralf Lutterbüse (6 out of 26 patents)

4. Patrick A Baeuerle (5 out of 35 patents)

5. Birgit Kohleisen (4 out of 7 patents)

Please report any incorrect information to [email protected]

Loading…